Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adenocarcinoma In Situ

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    121 result(s) found for: Adenocarcinoma In Situ. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006088-22 Sponsor Protocol Number: Gastripec-I Start Date*: 2011-03-28
    Sponsor Name:Klinik für Chirurgie, Charité Campus Virchow-Klinikum
    Full Title: Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carc...
    Medical condition: Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10042080 Stomach cancer LLT
    20.0 100000004864 10042081 Stomach cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004189-37 Sponsor Protocol Number: HCQHNLcancer Start Date*: 2022-03-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer
    Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078181 Laryngeal squamous cell carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030964 Oral carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037352 Pulmonary carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025122 Lung squamous cell carcinoma stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000318-12 Sponsor Protocol Number: MITOCERV3 Start Date*: 2020-02-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012983-14 Sponsor Protocol Number: DMS32212R Start Date*: 2009-10-21
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with...
    Medical condition: Newly diagnosed or relapsed advanced (Stage IIIB/IV) primary adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025031 Lung adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001605-42 Sponsor Protocol Number: 20060317 Start Date*: 2008-07-14
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effi...
    Medical condition: Unrespectable locally advanced or metastatic gastric or esophagogastric unction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10017759 Gastric cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-000273-81 Sponsor Protocol Number: UC-GIG-2203 Start Date*: 2022-09-13
    Sponsor Name:UNICANCER
    Full Title: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurre...
    Medical condition: Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003965-27 Sponsor Protocol Number: OCTO-072 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Oxford
    Full Title: A phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other sold cancers using time to event continual reassessment method
    Medical condition: Stage A1 and B: Oesophageal carcinoma Stage A2: Any advanced solid tumours (carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-021118-47 Sponsor Protocol Number: LAOXCAP Start Date*: 2010-10-07
    Sponsor Name:Fundación Hospital de Madrid
    Full Title: Estudio fase II, abierto, multicéntrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinación de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacient...
    Medical condition: pacientes HER2/ErbB2 positivo con adenocarcinoma gástrico, de la unión gastroesofágica o del tercio inferior del esófago en estadio IB - III.
    Disease: Version SOC Term Classification Code Term Level
    13 10001150 Adenocarcinoma gástrico LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001757-27 Sponsor Protocol Number: MK-3475-859 Start Date*: 2018-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previous...
    Medical condition: HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    21.0 100000004864 10058526 Oesophageal adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) PL (Ongoing) DE (Ongoing) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003905-24 Sponsor Protocol Number: AP311736 Start Date*: 2014-02-12
    Sponsor Name:SFJ Pharma Ltd. II
    Full Title: ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001512-34 Sponsor Protocol Number: DS8201-A-U205 Start Date*: 2019-10-02
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE...
    Medical condition: Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    21.1 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004299-38 Sponsor Protocol Number: ESPAC-4Version:7Date:21/07/2011 Start Date*: 2008-09-17
    Sponsor Name:The University of Liverpool [...]
    1. The University of Liverpool
    2. The Royal Liverpool and Broadgreen University Hospital NHS Trust
    Full Title: European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers.
    Medical condition: Resectable pancreatic or peri-ampullary cancers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    14.1 100000004864 10034446 Periampullary carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Restarted) FI (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007345-31 Sponsor Protocol Number: 3144A2-3004-WW Start Date*: 2009-08-05
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
    Medical condition: Her2 overexpressed, early stage breast cancer (adjuvant treatment stage)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006173 Breast adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) SK (Completed) CZ (Completed) ES (Completed) BE (Completed) GB (Completed) LT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) GR (Completed) MT (Completed) BG (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001032-12 Sponsor Protocol Number: PANTHERA Start Date*: 2008-10-28
    Sponsor Name:Universitätsklinikum Schleswig-Holstein
    Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2016-004502-34 Sponsor Protocol Number: CA209-914 Start Date*: 2017-08-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Parti...
    Medical condition: Early stage localized Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001105-85 Sponsor Protocol Number: P_2017_007 Start Date*: 2018-06-12
    Sponsor Name:Centre Hospitalier Annecy Genevois
    Full Title: A multicenter phase II study evaluating denosumab (XGEVA®) in combination with nivolumab (OPDIVO®) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squ...
    Medical condition: second-line therapy for patients with stage IV non-small cell lung cancer (squamous and non-squamous) with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004872-17 Sponsor Protocol Number: IC2020-04 Start Date*: 2021-03-18
    Sponsor Name:INSTITUT CURIE
    Full Title: A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB) before Breast Cancer Surgery: Effects on acute Postoperative Pain
    Medical condition: Nervous Block erector spinae plane (ESP) or paravertebral block (PVB) preoperatively in women with breast adenocarcinoma without metastasis or breast in situ adenocarcinoma to by treated either by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10003034 Application site anesthesia LLT
    20.0 100000004864 10006290 Breast and nipple neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA